Bristol-Myers Z Score

BMYMP
 Stock
  

USD 1,287  0.00  0.00%   

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Continue to Bristol-Myers Squibb Piotroski F Score and Bristol-Myers Squibb Valuation analysis.
  

Bristol-Myers Z Score Analysis

Bristol-Myers Squibb's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Z Score 
 = 
Sum Of  
 
5 Factors 
More About Z Score | All Equity Analysis
First Factor
 = 
1.2 * (
Working Capital
/
Total Assets )
Second Factor
 = 
1.4 * (
Retained Earnings
/
Total Assets )
Thrid Factor
 = 
3.3 * (
EBITAD
/
Total Assets )
Fouth Factor
 = 
0.6 * (
Market Value of Equity
/
Total Liabilities )
Fifth Factor
 = 
0.99 * (
Revenue
/
Total Assets )
To calculate Z-Score one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. Z-Score can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition

In accordance with the company's disclosures, Bristol-Myers Squibb has a Z Score of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Drug Manufacturers - Major industry. The z score for all United States stocks is 100.0% higher than that of the company.

Bristol-Myers Z Score Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bristol-Myers Squibb's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the otc pink sheets which would be a good addition to a portfolio. Peer analysis of Bristol-Myers Squibb could also be used in its relative valuation, which is a method of valuing Bristol-Myers Squibb by comparing valuation metrics of similar companies.
Bristol-Myers Squibb is currently under evaluation in z score category among related companies.

Bristol-Myers Fundamentals

About Bristol-Myers Squibb Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bristol-Myers Squibb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bristol-Myers Squibb using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bristol-Myers Squibb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug Manufacturers - Major classification in USA and is traded on OTC Market. It employs 23700 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Bristol-Myers Squibb without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Technical Analysis Now

   

Technical Analysis

Check basic technical indicators and analysis based on most latest market data
All  Next Launch Module

Pair Trading with Bristol-Myers Squibb

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol-Myers Squibb position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol-Myers Squibb will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Bristol-Myers Squibb could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol-Myers Squibb when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol-Myers Squibb - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol-Myers Squibb to buy it.
The correlation of Bristol-Myers Squibb is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol-Myers Squibb moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol-Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol-Myers Squibb can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Bristol-Myers Squibb Piotroski F Score and Bristol-Myers Squibb Valuation analysis. You can also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Complementary Tools for analysis

When running Bristol-Myers Squibb price analysis, check to measure Bristol-Myers Squibb's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol-Myers Squibb is operating at the current time. Most of Bristol-Myers Squibb's value examination focuses on studying past and present price action to predict the probability of Bristol-Myers Squibb's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bristol-Myers Squibb's price. Additionally, you may evaluate how the addition of Bristol-Myers Squibb to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Please note, there is a significant difference between Bristol-Myers Squibb's value and its price as these two are different measures arrived at by different means. Investors typically determine Bristol-Myers Squibb value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol-Myers Squibb's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.